Loading patent…
AssigneeXintela AB
InventorsEvy Lundgren Åkerlund, Folke Sjöberg, Hooi Ching Lim, Ahmed Elserafy, Moustafa Elmasry
Estimating the term…
The present invention relates to therapeutics and methods for treating skin defects using compositions comprising integrin al0-selected Mesenchymal Stem Cells (MSCs) Disclosed herein are integrin α10-selected MSC populations and culture conditions that enhance cell viability, paracrine activity, and regenerative function when administered to damaged skin tissue. The compositions promote wound healing, modulate inflammatory responses, and support re-epithelialization. Further disclosed herein are dosing parameters and administration routes suitable for improving healing outcomes in acute and chronic skin defects.
A method for treatment and/or regeneration of a skin defect, comprising administering a therapeutically effective amount of a composition comprising integrin alpha10-selected Mesenchymal Stem Cells (MSCs) to a subject in need thereof, wherein at least 60% of the MSCs express integrin alpha10 subunit.
A method for prevention of fibrosis of the skin comprising administering a therapeutically effective amount of a composition comprising integrin alpha10-selected Mesenchymal Stem Cells (MSCs) to a subject in need thereof.
A method for regeneration of skin at the site of a skin defect and/or for reducing scar formation resulting from healing of a skin defect comprising administering a composition comprising integrin alpha10-selected Mesenchymal Stem Cells (MSCs) to a subject in need thereof.
Dependencies are inferred from the claim text.